#1 Clinical Trials Search in Europe

Ramucirumab

Ramucirumab is an innovative drug being studied in various clinical trials for its potential in treating different types of cancer. These trials aim to evaluate its safety, effectiveness, and optimal dosing when used alone or in combination with other treatments. The research spans multiple cancer types, including lung, gastric, and pancreatic cancers, offering hope for improved outcomes in advanced stages of these diseases.

Table of Contents

What is Ramucirumab?

Ramucirumab is a medication used in the treatment of various types of cancer. It is also known by its brand name Cyramza[1]. Ramucirumab is classified as a monoclonal antibody, which is a type of protein designed to target specific cells in the body[3].

How Ramucirumab Works

Ramucirumab works by targeting a specific protein in the body called vascular endothelial growth factor receptor 2 (VEGFR-2). This protein plays a crucial role in the formation of new blood vessels that feed tumors. By blocking VEGFR-2, Ramucirumab helps to cut off the blood supply to cancer cells, potentially slowing or stopping their growth[3].

Conditions Treated with Ramucirumab

Ramucirumab is used to treat several types of advanced or metastatic cancers, including:

  • Gastric (stomach) cancer: Including cancer of the gastroesophageal junction (where the esophagus meets the stomach)[1]
  • Non-small cell lung cancer (NSCLC)[2]
  • Colorectal cancer[3]
  • Hepatocellular carcinoma (liver cancer)

It is typically used when other treatments have not been effective or when the cancer has spread to other parts of the body.

How Ramucirumab is Administered

Ramucirumab is usually given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The dosage and frequency can vary depending on the specific condition being treated and the patient’s individual needs. Some common dosing regimens include:

  • 8 mg/kg every 2 weeks[1]
  • 10 mg/kg every 3 weeks[10]

In some cases, Ramucirumab may be given in combination with other cancer medications, such as paclitaxel or chemotherapy drugs[1][9].

Current Clinical Trials

Researchers are continuously studying Ramucirumab to understand its effectiveness better and explore new ways to use it. Some ongoing clinical trials are investigating:

  • The use of Ramucirumab as a maintenance therapy after initial chemotherapy for gastric cancer[1]
  • Combining Ramucirumab with immunotherapy drugs for lung cancer[2]
  • The effectiveness of Ramucirumab in elderly patients with gastric cancer[9]
  • Using Ramucirumab in combination with other targeted therapies for lung cancer[10]

Potential Side Effects

Like all medications, Ramucirumab can cause side effects. Some common side effects may include:

  • Fatigue
  • Decreased appetite
  • Abdominal pain
  • High blood pressure
  • Low white blood cell count (which can increase the risk of infections)

Your healthcare team will monitor you closely for any side effects and can help manage them if they occur[1].

Future Research and Combinations

Researchers are exploring new ways to use Ramucirumab, including:

  • Testing its effectiveness when given as an injection under the skin (subcutaneous injection) instead of through an IV[5]
  • Investigating its use in pediatric patients with solid tumors[4]
  • Studying Ramucirumab in combination with other cancer drugs to potentially improve outcomes[8]

These ongoing studies aim to expand our understanding of how Ramucirumab can be used most effectively to help patients with various types of cancer.

Aspect Details
Drug Name Ramucirumab (also known as Cyramza, LY3009806, IMC-1121B)
Mechanism of Action VEGFR-2 antagonist, inhibits angiogenesis
Cancer Types Studied NSCLC, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma, advanced solid tumors
Administration Methods Intravenous (IV), some trials exploring subcutaneous
Common Dosages 8 mg/kg every 2 weeks, 10 mg/kg every 3 weeks (varies by trial)
Combination Therapies Studied with chemotherapy drugs (paclitaxel, gemcitabine, platinum-based) and other targeted therapies
Key Outcome Measures Progression-free survival, overall survival, objective response rate, safety profile
Special Populations Some trials focus on elderly patients or specific genetic profiles (e.g., ALK-rearranged lung cancers)

FAQ

  • What is Ramucirumab and how does it work? Ramucirumab is a targeted therapy drug that works as a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist. It blocks the growth of new blood vessels that feed tumors, potentially slowing or stopping cancer growth.
  • What types of cancer are being studied with Ramucirumab? Clinical trials are exploring Ramucirumab's effectiveness in various cancers, including non-small cell lung cancer (NSCLC), gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma, and other advanced solid tumors.
  • How is Ramucirumab administered in these trials? Ramucirumab is typically administered intravenously (IV). The dosage and frequency vary between trials, with common regimens including 8 mg/kg every 2 weeks or 10 mg/kg every 3 weeks. Some studies are also exploring subcutaneous administration.
  • What are the potential side effects of Ramucirumab? While side effects can vary, common ones may include fatigue, decreased appetite, and high blood pressure. Trials are closely monitoring for adverse events and adjusting dosages as needed to ensure patient safety.
  • Can Ramucirumab be combined with other cancer treatments? Yes, many trials are studying Ramucirumab in combination with other treatments such as chemotherapy drugs (like paclitaxel, gemcitabine, or platinum-based drugs) or other targeted therapies to potentially enhance its effectiveness against cancer.

Ongoing Clinical Trials on Ramucirumab

  • Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

    Recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Norway

  • Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

    Recruiting

    1 1 1
    Investigated drugs:
    France Greece Italy Portugal Romania Spain

  • A study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study of Bemarituzumab with Irinotecan, Paclitaxel, Ramucirumab, or Trifluridine/Tipiracil for Advanced Stomach or Gastroesophageal Cancer in Patients After Chemotherapy

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Germany Spain

  • Study on the Effectiveness and Safety of AZD0901 Compared to Standard Treatments for Adults with Advanced Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study of Ramucirumab and Erlotinib for Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy

  • Study of ALX148 with Trastuzumab, Ramucirumab, and Paclitaxel for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia France Italy Spain

  • Study of AFM24 and Atezolizumab for Patients with Advanced or Metastatic EGFR-expressing Cancers

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Poland Spain

Glossary

  • VEGFR-2: Vascular Endothelial Growth Factor Receptor 2, a protein on cell surfaces that plays a crucial role in the formation of new blood vessels. Ramucirumab targets this receptor to inhibit tumor blood supply.
  • Non-small cell lung cancer (NSCLC): A type of lung cancer that is the most common form, accounting for about 80-85% of all lung cancers. It grows and spreads more slowly than small cell lung cancer.
  • Gastroesophageal junction adenocarcinoma: A type of cancer that forms in the area where the esophagus joins the stomach.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST criteria: Response Evaluation Criteria In Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.
  • Maximum tolerated dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Anti-angiogenic agent: A substance that inhibits the growth of new blood vessels, which can help slow or stop tumor growth.

References

  1. https://clinicaltrials.gov/study/NCT02934464
  2. https://clinicaltrials.gov/study/NCT03904108
  3. https://clinicaltrials.gov/study/NCT05800418
  4. https://clinicaltrials.gov/study/NCT02564198
  5. https://clinicaltrials.gov/study/NCT04557384
  6. https://clinicaltrials.gov/study/NCT02443883
  7. https://clinicaltrials.gov/study/NCT01983878
  8. https://clinicaltrials.gov/study/NCT03745430
  9. https://clinicaltrials.gov/study/NCT03760822
  10. https://clinicaltrials.gov/study/NCT06007937